Type 2 & other diabetes

New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: A nationwide population-based cohort study

Diabetes MetabPublished Nationwide population-based cohort study

Main finding · GI cancersResult — go to the resultAdjusted hazard ratio 0.90 95 % CI 0.82–0.99

Authors' conclusion

For T2D patients, SGLT2i use was associated with a diminished pancreatic cancer risk compared to oGLMs. Future studies should ascertain the potential protective effect of SGLT2is against pancreatic cancer.

Study context

Population
Patients with T2D, nationwide National Health Insurance Service database, Republic of Korea, September 2014 to June 2020propensity score matched
Participants
59,954 vs 59,954
Exposure
SGLT2i vs other glucose lowering medications
  • SGLT2isn = 59,954
  • Other glucose lowering medications (oGLMs)n = 59,954reference
Outcome
Incidence of gastrointestinal (GI) cancers (stomach, colorectal, liver and pancreatic)
Methodological detailsactive-comparator, new-user, propensity score matched
  • Active-comparator
  • New-user
  • Propensity score matched

Main finding

GI cancers

Adjusted hazard ratio

0.90

95 % CI 0.82–0.99

Events by group

SGLT2is

814

events

oGLMs

916

events

SGLT2isvs oGLMs
aHR 0.90 (95 % CI 0.82–0.99)

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeAdjusted HR (95 % CI)
Pancreatic cancerOnly cancer type significantly lower with SGLT2is · propensity score matched0.72 (0.55–0.95)

Events

OutcomeSGLT2isoGLMs
Deaths · observation period7941,140

Pancreatic cancer, entire cohort

Multivariable-adjusted HR for pancreatic cancer in the entire cohort
0.70 (95 % CI: 0.56 to 0.88)

Original publication

New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: A nationwide population-based cohort study. Diabetes Metab. Published 7 January 2025. doi:10.1016/j.diabet.2025.101605

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.